Shanghai ZJ Bio-Tech CoSHSE:688317 -4.33%68 PB Ratio is 0.91 as of Jun. 25, 2026, which is 25% below its 10-year median of 1.22. GuruFocus rates SHSE:688317 with a GF Score™ of 68/100 and a GF Value™ of ¥9.94 (Significantly Overvalued). The stock has 2 warning signs investors should review. Among 788 Medical Devices & Instruments companies, Shanghai ZJ Bio-Tech Co ranks better than 81.47% on this metric.
Shanghai ZJ Bio-Tech Co Ltd stock PB Ratio (=0.95) is close to 1-year low of 0.95.
The historical rank and industry rank for Shanghai ZJ Bio-Tech Co's PB Ratio or its related term are showing as below:
SHSE:688317'
s PB Ratio Range Over the Past 10 Years
Min: 0.71 Med: 1.22 Max: 8.41
Current: 0.91
During the past 13 years, Shanghai ZJ Bio-Tech Co's highest PB Ratio was 8.41. The lowest was 0.71. And the median was 1.22.
SHSE:688317's PB Ratio is ranked better than 81.47% of 788
companies
in the Medical Devices & Instruments industry
Industry Median: 2.045
vs SHSE:688317: 0.91
During the past 12 months, Shanghai ZJ Bio-Tech Co's average Book Value Per Share Growth Rate was -6.50% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was -6.90% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was 7.60% per year.
During the past 10 years, the average Book Value Per Share Growth Rate was 28.50% per year.
During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of Shanghai ZJ Bio-Tech Co was 76.60% per year. The lowest was -6.90% per year. And the median was 35.45% per year.
Back to Basics: PB Ratio
Shanghai ZJ Bio-Tech Co (SHSE:688317) PB Ratio Explanation
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, Shanghai ZJ Bio-Tech Co's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Shanghai ZJ Bio-Tech Co PB Ratio vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Shanghai ZJ Bio-Tech Co's PB Ratio distribution charts can be found below:
* The bar in red indicates where Shanghai ZJ Bio-Tech Co's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Shanghai ZJ Bio-Tech Co (SHSE:688317) has a PB Ratio of 0.91 as of Jun. 25, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Shanghai ZJ Bio-Tech Co and its competitors. This is 25% below median its historical median of 1.22. Over the past decade, Shanghai ZJ Bio-Tech Co's PB Ratio has ranged from 0.71 to 8.41. According to the industry distribution chart, Shanghai ZJ Bio-Tech Co ranks #146 out of 788 companies in the Medical Devices & Instruments industry, placing it in the top 18.5%.
Is Shanghai ZJ Bio-Tech Co's PB Ratio too high?
Shanghai ZJ Bio-Tech Co's current PB Ratio of 0.91 is 25% below median its 10-year median of 1.22. Over the past 10 years, this metric has ranged from a low of 0.71 to a high of 8.41. The Medical Devices & Instruments industry median PB Ratio is 2.05. Shanghai ZJ Bio-Tech Co's value of 0.91 is 55.5% below this industry median. Based on the distribution chart, Shanghai ZJ Bio-Tech Co ranks #146 out of 788 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Shanghai ZJ Bio-Tech Co has a GF Score™ of 68/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Shanghai ZJ Bio-Tech Co's PB Ratio compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Shanghai ZJ Bio-Tech Co ranks #146 out of 788 companies for PB Ratio. This places Shanghai ZJ Bio-Tech Co in the top 19% of its industry — outperforming the majority of peers. The industry median PB Ratio is 2.05. Shanghai ZJ Bio-Tech Co's value of 0.91 is 55.5% below this benchmark. Historically, Shanghai ZJ Bio-Tech Co's own PB Ratio has ranged from 0.71 to 8.41 over the past decade. While the company's 10-year median is 1.22 vs. the industry median of 2.05, Shanghai ZJ Bio-Tech Co has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Medical Devices & Instruments company?
The median PB Ratio among Medical Devices & Instruments companies is 2.05, based on 788 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Shanghai ZJ Bio-Tech Co's current PB Ratio of 0.91 is 55.5% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Shanghai ZJ Bio-Tech Co and its competitors. For the Medical Devices & Instruments industry, the median PB Ratio is 2.05 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Shanghai ZJ Bio-Tech Co's current PB Ratio is 0.91, which is 25% below median its own 10-year median of 1.22. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Shanghai ZJ Bio-Tech Co stock overvalued right now?
Based on GuruFocus' analysis, Shanghai ZJ Bio-Tech Co (SHSE:688317) is currently considered Significantly Overvalued. The stock's GF Value™ is ¥9.94, compared to a current price of ¥15.68 — trading 57.7% above its estimated fair value. The current PB Ratio is 0.91, which is 25% below median its 10-year median of 1.22 and 55.5% below the Medical Devices & Instruments industry median of 2.05. Shanghai ZJ Bio-Tech Co's overall GF Score™ is 68/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Shanghai ZJ Bio-Tech Co (SHSE:688317), the current PB Ratio is 0.91 as of Jun. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Shanghai ZJ Bio-Tech Co (SHSE:688317) Overvalued in 2026?
Based on GuruFocus' analysis, Shanghai ZJ Bio-Tech Co stock appears to be overvalued.
The current stock price of ¥15.68 is trading 57.7% above its estimated GF Value™ of ¥9.94.
GuruFocus considers Shanghai ZJ Bio-Tech Co to be Significantly Overvalued.
Key valuation signals for SHSE:688317:
PB Ratio: 0.91 (25% below median its 10-year median of 1.22)
GF Value™: ¥9.94 vs. price of ¥15.68 (57.7% above fair value)
Industry Position: 55.5% below the Medical Devices & Instruments median (#146 of 788)
No single metric tells the full story. See the SHSE:688317 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Shanghai ZJ Bio-Tech Co Ltd is engaged in research and development, production and sales of genetic diagnostic reagents and instruments and equipment. The rapid real-time fluorescent PCR diagnostic test reagents developed by the company are mainly used in clinical medicine, public health emergencies, entry-exit inspection and quarantine, food inspection, animal husbandry, aquaculture and other fields.
68GF Score
Get the complete analysis for SHSE:688317
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:688317 has been successfully added to your 
